ASCO 2016

Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study

Conference Correspondent - ASCO 2016

Alectinib (ALC) showed promising efficacy and tolerability in the phase 1/2 study (AF-001JP).1,2 Nokihara and colleagues conducted a randomized open-label phase 3 trial (J-ALEX study) to prove superior progression-free survival (PFS) of ALC to crizotinib (CRZ) in ALK-positive non–small-cell lung [ Read More ]

A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13

Conference Correspondent - ASCO 2016

Various therapeutic strategies are available for non–small-cell lung cancer (NSCLC) patients who develop disease progression on first-line EGFR tyrosine kinase inhibitor (TKI) therapy. However, it has not been established which cytotoxic regimens are preferable for these patients. Yoo and colleagues [ Read More ]